Compare HCKT & AVXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCKT | AVXL |
|---|---|---|
| Founded | 1991 | 2004 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 392.0M | 388.7M |
| IPO Year | 1998 | 2013 |
| Metric | HCKT | AVXL |
|---|---|---|
| Price | $14.06 | $4.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $17.00 | ★ $22.00 |
| AVG Volume (30 Days) | 320.3K | ★ 1.0M |
| Earning Date | 05-19-2026 | 04-27-2026 |
| Dividend Yield | ★ 3.38% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.46 | N/A |
| Revenue | ★ $285,862,000.00 | N/A |
| Revenue This Year | $2.55 | N/A |
| Revenue Next Year | $5.07 | N/A |
| P/E Ratio | $30.87 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $12.76 | $2.86 |
| 52 Week High | $29.52 | $13.99 |
| Indicator | HCKT | AVXL |
|---|---|---|
| Relative Strength Index (RSI) | 41.28 | 56.55 |
| Support Level | $12.76 | $3.60 |
| Resistance Level | $21.13 | $4.88 |
| Average True Range (ATR) | 0.57 | 0.26 |
| MACD | 0.26 | 0.05 |
| Stochastic Oscillator | 62.56 | 57.57 |
The Hackett Group Inc is an IP platform-based Generative Artificial Intelligence (Gen AI) strategic consulting and executive advisory digital transformation firm. The Hackett Group provides dedicated expertise in Gen AI-enabled enterprise transformation services across the front, mid and back office areas, including its highly recognized Oracle, SAP, OneStream and Coupa implementation offerings. It operates in three segments Oracle Solutions, SAP Solutions, and Global S&BT. It generates the majority of its revenue from the Global S&BT segment in the United States.
Anavex Life Sciences Corp is a clinical stage biopharmaceutical company engaged in the development of differentiated therapeutics by applying precision medicine to central nervous system(CNS) diseases with high unmet need. It analyzes genomic data from clinical trials to identify biomarkers, which are used in the analysis of its clinical trials for the treatment of neurodegenerative and neurodevelopmental diseases. The company focuses on developing treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders. Its pipeline includes ANAVEX 2-73 and ANAVEX 3-71 and several other compounds in different stages of clinical and pre-clinical development.